Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week
New York, January 31, 2026, 10:29 EST — The market has closed. Johnson & Johnson shares edged down 3 cents to $227.25 on Friday after a U.S. judge dismissed a lawsuit accusing the company of fraud related to its talc bankruptcy approach. The plaintiffs claimed J&J employed a “Texas two-step,” moving talc liabilities into a subsidiary that filed for bankruptcy to stall cancer lawsuits. Judge Michael Shipp ruled they hadn’t proven any real harm caused by the delay. J&J’s litigation head Erik Haas slammed the claims as “wholly meritless,” while the plaintiffs’ attorney said they’re considering an appeal.